Literature DB >> 22163139

Takotsubo cardiomyopathy associated with titration of duloxetine.

Kristopher J Selke1, Gaurav Dhar, Joel M Cohn.   

Abstract

Takotsubo cardiomyopathy is characterized by transient multisegmental left ventricular dysfunction, dynamic electrocardiographic changes that mimic acute myocardial infarction, and the absence of obstructive coronary disease. Takotsubo cardiomyopathy has been solidly associated with antecedent emotional and physical stressors that trigger catecholamine surges, which lead to coronary vasospasm or direct myocardial injury. Some medications can also cause catecholamine surges, although this phenomenon is not as well described. Duloxetine is a combined serotonin and norepinephrine reuptake inhibitor (SNRI). The basic goal of SNRIs is to increase catecholamine levels in neuronal tissue. However, the increased catecholamine levels may also affect the cardiovascular system.Herein, we report the case of a 59-year-old woman whose takotsubo cardiomyopathy was temporally associated with the titration of duloxetine. The duloxetine therapy was subsequently discontinued, and the patient's left ventricular function recovered completely 1 month after the index event. The purpose of this report is to alert clinicians to a possible association between SNRI medications and takotsubo cardiomyopathy.

Entities:  

Keywords:  Adrenergic uptake inhibitors/adverse effects; cardiomyopathies/chemically induced; catecholamines/blood; chest pain/etiology; drug therapy/adverse effects; duloxetine; norepinephrine/blood; serotonin uptake inhibitors/adverse effects; takotsubo cardiomyopathy/chemically induced/physiopathology; ventricular dysfunction, left/chemically induced

Mesh:

Substances:

Year:  2011        PMID: 22163139      PMCID: PMC3231522     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  12 in total

1.  Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine.

Authors:  Marian Christoph; Bernd Ebner; Dirk Stolte; Karim Ibrahim; Steffen Kolschmann; Ruth H Strasser; Steffen Schön
Journal:  Eur Neuropsychopharmacol       Date:  2010-05-07       Impact factor: 4.600

Review 2.  Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review.

Authors:  Monica Gianni; Francesco Dentali; Anna Maria Grandi; Glen Sumner; Rajesh Hiralal; Eva Lonn
Journal:  Eur Heart J       Date:  2006-05-23       Impact factor: 29.983

3.  Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists.

Authors:  Jacob Abraham; James O Mudd; Navin K Kapur; Navin Kapur; Kelly Klein; Hunter C Champion; Ilan S Wittstein
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

4.  A case of apical ballooning cardiomyopathy associated with duloxetine.

Authors:  Benjamin R Bergman; Harmony R Reynolds; Adam H Skolnick; Demetrio Castillo
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Clinical characteristics of tako-tsubo cardiomyopathy.

Authors:  Venkatesan Vidi; Vinutha Rajesh; Premranjan P Singh; Jayanta T Mukherjee; Rodrigo M Lago; David M Venesy; Sergio Waxman; Christopher T Pyne; Thomas C Piemonte; David E Gossman; Richard W Nesto
Journal:  Am J Cardiol       Date:  2009-06-18       Impact factor: 2.778

7.  Neurohumoral features of myocardial stunning due to sudden emotional stress.

Authors:  Ilan S Wittstein; David R Thiemann; Joao A C Lima; Kenneth L Baughman; Steven P Schulman; Gary Gerstenblith; Katherine C Wu; Jeffrey J Rade; Trinity J Bivalacqua; Hunter C Champion
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

8.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy.

Authors:  Vincent J Colucci; Bradley D Berry
Journal:  Ann Pharmacother       Date:  2008-04-29       Impact factor: 3.154

10.  Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.

Authors:  S Neil Vaishnavi; Charles B Nemeroff; Susan J Plott; Srinivas G Rao; Jay Kranzler; Michael J Owens
Journal:  Biol Psychiatry       Date:  2004-02-01       Impact factor: 13.382

View more
  8 in total

1.  Initial clinical presentation of Takotsubo cardiomyopathy with-a focus on electrocardiographic changes: A literature review of cases.

Authors:  Erick Francisco Sanchez-Jimenez
Journal:  World J Cardiol       Date:  2013-07-26

2.  Hypertension, tachycardia, and reversible cardiomyopathy temporally associated with milnacipran use.

Authors:  Mervyn B Forman; Paul G Sutej; Edwin K Jackson
Journal:  Tex Heart Inst J       Date:  2011

3.  Selective Serotonin-norepinephrine Reuptake Inhibitors-induced Takotsubo Cardiomyopathy.

Authors:  Rahul Vasudev; Upamanyu Rampal; Hiten Patel; Kunal Patel; Mahesh Bikkina; Fayez Shamoon
Journal:  N Am J Med Sci       Date:  2016-07

Review 4.  Role of Depression and Anxiety Disorders in Takotsubo Syndrome: The Psychiatric Side of Broken Heart.

Authors:  Federico Oliveri; Harshit K Goud; Lubna Mohammed; Zainab Mehkari; Moiz Javed; Aldanah Althwanay; Farah Ahsan; Ian H Rutkofsky
Journal:  Cureus       Date:  2020-09-11

Review 5.  Takotsubo Cardiomyopathy: Medical and Psychiatric Aspects. Role of Psychotropic Medications in the Treatment of Adults with "Broken Heart" Syndrome.

Authors:  Valeriy Zvonarev
Journal:  Cureus       Date:  2019-07-19

Review 6.  Update of Takotsubo cardiomyopathy: Present experience and outlook for the future.

Authors:  Anastasiia V Bairashevskaia; Sofiya Y Belogubova; Mikhail R Kondratiuk; Daria S Rudnova; Susanna S Sologova; Olga I Tereshkina; Esma I Avakyan
Journal:  Int J Cardiol Heart Vasc       Date:  2022-03-07

Review 7.  Psychiatric Illness in Takotsubo (Stress) Cardiomyopathy: A Review.

Authors:  Arash Nayeri; Eric Rafla-Yuan; Srikanth Krishnan; Boback Ziaeian; Martin Cadeiras; John A McPherson; Quinn S Wells
Journal:  Psychosomatics       Date:  2018-02-02       Impact factor: 2.386

8.  Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy.

Authors:  Kezia Lizardo; Janeesh Plakkal Ayyappan; Usha Ganapathi; Walderez O Dutra; Yunping Qiu; Louis M Weiss; Jyothi F Nagajyothi
Journal:  Dis Markers       Date:  2019-12-20       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.